PLx Pharma Inc. to Present at Janney Healthcare Conference on September 18
September 10 2018 - 4:30PM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
late-stage specialty pharmaceutical company focused on
commercializing two patent-protected products, Vazalore™ 325 mg and
Vazalore™ 81 mg (referred to together as “Vazalore”™), announced
today that Natasha Giordano, President and Chief Executive Officer,
and Rita O’Connor, Chief Financial Officer, will present at the
Janney Healthcare Conference as follows:
Date: |
Tuesday,
September 18, 2018 |
Time: |
11:35
a.m. Eastern Daylight Time |
Location: |
The Union
League Club, NY, NY |
Webcast: |
https://cc.callinfo.com/registration/#/?meeting=1t1tejlyh9cax&campaign=1gph83r1k7kyy |
The presentation will be webcast live at the aforementioned
time, and archived for 30 days thereafter, via the Company’s
website at www.plxpharma.com under the News & Events
section.
About VazaloreVazalore 325 mg is
an FDA-approved aspirin product being developed to provide
high-risk cardiovascular and stroke patients with more reliable and
predictable antiplatelet efficacy as compared to enteric-coated
aspirin, while also reducing the adverse gastric events common in
an acute setting. PLx is focused on manufacturing, scale-up and
label finalization for Vazalore 325 mg aspirin dosage form and
preparing an sNDA for Vazalore 81 mg maintenance dose form.
About PLx Pharma Inc.PLx Pharma
Inc. is a late-stage specialty pharmaceutical company focused
on developing its clinically validated and patent-protected
PLxGuard™ delivery system to provide effective and safe aspirin
products. The PLxGuard delivery system works by targeting delivery
of active pharmaceutical ingredients (API) to various portions of
the gastrointestinal (GI) tract. PLx believes this has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce GI side effects in an acute
setting—including erosions, ulcers and bleeding—associated with
aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson, In-Site
Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
Source: PLx Pharma Inc.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Apr 2023 to Apr 2024